Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology

Sara Fatima

doi:10.1007/978-981-95-0221-9_10

Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology

Sara Fatima

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Protein-based therapeutics, including monoclonal antibodies, cytokines, enzymes, and vaccines, have transformed the landscape of modern medicine, addressing previously untreatable diseases with high specificity and minimal off-target effects. Biologics constitute a rapidly expanding segment within the pharmaceutical market, propelled by progress in the fields of genetic engineering, engineered DNA technologies, and hybridoma approaches. Among the blockbuster protein therapies are adalimumab (Humira[[sup]]®[[/sup]]) for autoimmune illnesses and trastuzumab (Herceptin[[sup]]®[[/sup]]) for breast cancer (Walsh 2014; Strohl 2018).

Original language	English (Ireland)
Title of host publication	Freeze-drying Technology in Pharmaceutical and Biomedical Product Development
Subtitle of host publication	Impact, Progress and Challenges of Lyophilization
Publisher	Springer Nature Singapore
Chapter	10
Pages	227
Number of pages	263
ISBN (Electronic)	978-981-95-0221-9
ISBN (Print)	978-981-95-0220-2
DOIs	https://doi.org/10.1007/978-981-95-0221-9_10
Publication status	Published - 1 Jan 2025

Access to Document

10.1007/978-981-95-0221-9_10

Cite this

@inbook{9d87ed306e2b45f88699ef6a94fffe40,

title = "Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology",

abstract = "Protein-based therapeutics, including monoclonal antibodies, cytokines, enzymes, and vaccines, have transformed the landscape of modern medicine, addressing previously untreatable diseases with high specificity and minimal off-target effects. Biologics constitute a rapidly expanding segment within the pharmaceutical market, propelled by progress in the fields of genetic engineering, engineered DNA technologies, and hybridoma approaches. Among the blockbuster protein therapies are adalimumab (Humira[[sup]]{\textregistered}[[/sup]]) for autoimmune illnesses and trastuzumab (Herceptin[[sup]]{\textregistered}[[/sup]]) for breast cancer (Walsh 2014; Strohl 2018).",

author = "Sara Fatima",

note = "Publisher Copyright: {\textcopyright} 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-981-95-0221-9\_10",

language = "English (Ireland)",

isbn = "978-981-95-0220-2",

pages = "227",

booktitle = "Freeze-drying Technology in Pharmaceutical and Biomedical Product Development",

publisher = "Springer Nature Singapore",

}

Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology. / Fatima, Sara.
Freeze-drying Technology in Pharmaceutical and Biomedical Product Development : Impact, Progress and Challenges of Lyophilization. Springer Nature Singapore, 2025. p. 227.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology

AU - Fatima, Sara

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Protein-based therapeutics, including monoclonal antibodies, cytokines, enzymes, and vaccines, have transformed the landscape of modern medicine, addressing previously untreatable diseases with high specificity and minimal off-target effects. Biologics constitute a rapidly expanding segment within the pharmaceutical market, propelled by progress in the fields of genetic engineering, engineered DNA technologies, and hybridoma approaches. Among the blockbuster protein therapies are adalimumab (Humira[[sup]]®[[/sup]]) for autoimmune illnesses and trastuzumab (Herceptin[[sup]]®[[/sup]]) for breast cancer (Walsh 2014; Strohl 2018).

AB - Protein-based therapeutics, including monoclonal antibodies, cytokines, enzymes, and vaccines, have transformed the landscape of modern medicine, addressing previously untreatable diseases with high specificity and minimal off-target effects. Biologics constitute a rapidly expanding segment within the pharmaceutical market, propelled by progress in the fields of genetic engineering, engineered DNA technologies, and hybridoma approaches. Among the blockbuster protein therapies are adalimumab (Humira[[sup]]®[[/sup]]) for autoimmune illnesses and trastuzumab (Herceptin[[sup]]®[[/sup]]) for breast cancer (Walsh 2014; Strohl 2018).

U2 - 10.1007/978-981-95-0221-9_10

DO - 10.1007/978-981-95-0221-9_10

M3 - Chapter

SN - 978-981-95-0220-2

SP - 227

BT - Freeze-drying Technology in Pharmaceutical and Biomedical Product Development

PB - Springer Nature Singapore

ER -

Solid-State Delivery and Stabilization of Therapeutic Proteins Using Freeze-Drying Technology

Abstract

Access to Document

Fingerprint

Cite this